News

AbstractTransthyretin cardiac amyloidosis (ATTR-CM) is increasingly recognized as a treatable cause of heart failure, while heart failure with preserved ejection…

AbstractImportance: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disorder caused by destabilization of serum transthyretin (sTTR). Acoramidis, an…

I-evuzamitide positron emission tomography/computed tomography (PET/CT) can help diagnose heart involvement in rare forms of amyloidosis as well as transthyretin-…

The U.S. Food and Drug Administration (FDA) has granted fast track designation to coramitug, an experimental treatment in late-stage clinical testing for…

The Food and Drug Administration (FDA) has granted Fast Track designation to coramitug for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM).…

Key TakeawaysATTR-CM results from TTR accumulation causing ventricular thickening and diastolic dysfunction, presenting with dyspnea, edema, congestion, tachycardia…

ATTR-CM is the zebra hiding among the horses. AI may finally be the tool that finds it. Experts Drs Kevin Alexander and Lily Stern explore what's working, what's…

The FDA granted Fast Track Designation to coramitug, an investigational anti-TTR antibody designed to clear existing amyloid deposits in ATTR cardiomyopathy.The US…

AboutThe purpose of this study is to investigate the effect of eplontersen compared to placebo on the reduction of serum TTR concentration and long-term safety in…

Transthyretin (ATTR) amyloidosis is a progressive fatal disease caused by the deposition of transthyretin derived amyloid fibrils in various organs [1]. The disease…